Biotech Stocks with Promising Technology Analyst Coverage Amedica Corporation and Amyris, Inc.
August 25 2016 - 1:00PM
InvestorsHub NewsWire
Last Wednesday, August 17th, Amedica
Corporation (NASDAQ:
AMDA), a developer of interbody implants manufactured
with medical-grade silicon nitride ceramic, announced they had
received a NASDAQ de-listing notice due to their share price being
under $1.00. This week AMDA shares jumped from $.64 per share on
Friday the 19th to $1.32 in intraday trading on
Wednesday. Read analyst report here
Amyris, Inc. (NASDAQ:
AMRS) provides various alternatives to a range of
petroleum-sourced products. On June 14th of this year
the company announced it had received a NASDAQ de-listing notice
due to their share price remaining under $1.00. The company has
until December 12th to remedy the de-listing criterion.
Read analyst report here
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements
and information, as defined within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and is subject to the Safe Harbor created by
those sections. This material contains statements about expected
future events and/or financial results that are forward-looking in
nature and subject to risks and uncertainties. Such forward-looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of the subject company in this report to be materially
different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
Information in this release is fact checked and produced on a best
efforts basis. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below. The subject Companies have not compensated Traders News
Source for the creation or dissemination of this report. Traders
News Source is the party responsible for issuing this
report/release and for hosting the full report on Traders News
Source website.
NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Traders News
Source whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Traders News Source
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Traders News Source
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
Traders News Source produces reports, articles, blogs, and
investment newsletters covering companies listed on NYSE and NASDAQ
exchanges. Traders News Source has two distinct and independent
operating segments. One produces non-compensated analyst and or
expert certified content generally in the form of press releases,
articles and reports. The other produces compensated content, which
typically consists of compensated investment newsletters, articles
and reports.
HIGH DEGREE OF RISK
There is an extremely high inherent risk when investing in micro
and small cap biotech securities that
have little to no revenue and are dependent upon an approval from
the development of their drug
pipeline. You could lose your entire investment.
Source: Traders News Source
Contact: editor@tradersnewssource.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Sep 2023 to Sep 2024